紫外分光光度法测定盐酸恩丹西酮氯化钠注射液含量

恩丹西酮(Ondansetron，枢复宁)为一止吐药，具有选择性拮抗5-HT3受体的作用，主要用于细胞毒抗癌药化疗及放射治疗引起的严重恶心及呕吐反应，其8μg／ml水溶液在249nm、267nm、310nm处有最大紫外吸收，故我们选择紫外分光光度法作为其含量测定的方法，并对此方法进行探索与方法学考察。     

RP-HPLC测定盐酸恩丹西酮注射液中盐酸恩丹西酮的含量

盐酸恩丹西酮(ondansetron hydrochloride)是一种高效并有高度选择性的5-羟色胺受体拮抗剂。临床上用于癌症药物化疗和放射性治疗引起的恶心呕吐。有文献用紫外分光光度法和高效毛细管区带电泳技术测定含量。未见用RP-HPLC法测定的报道，本文建立了用RP-HPLC法测定盐酸恩丹西酮注射液制剂中的盐酸恩丹西酮含量，经方法考察，本法简便、快速、准确、结果可靠，可用于本品质量控制和临床应用检测。     

乳酸-羟基乙酸共聚物微球的研究进展

通过整理和归纳国内外文献,介绍乳酸-羟基乙酸(PLGA)载药微球的制备方法和作为药物载体的应用。     

蛋白质/多肽药物聚乳酸/乳酸-羟基乙酸共聚物微球研究进展

缓释微粒给药系统是蛋白质/多肽药物传输系统的一个重要研究方向，聚乳酸和乳酸-羟基乙酸共聚物是制备缓释微球最常用的载体材料。蛋白质/多肽药物聚乳酸/乳酸-羟基乙酸共聚物微球常用的制备方法包括溶剂萃取/挥发法(复乳法)、相分离法和喷雾干燥法。本文总结了微球制备中面临的难点如蛋白质/多肽药物稳定性、包封率、药物突释和药物吸附等问题，并综述了保持药物结构稳定性和生物活性、提高包封率、改善药物释放曲线等微球制备方法和进展。     

乳酸/羟基乙酸共聚物分子量对艾塞那肽微球性质的影响

目的:制备艾塞那肽一乳酸/羟基乙酸共聚物(PLGA)微球,并研究PLGA分子量对微球性质的影响.方法:选用不同分子量的PLGA,采用复乳法制备艾塞那肽PLGA微球;对微球的粒径、载药量、包封率和体外释放等指标进行测定.结果:PLGA分子量对艾塞那肽PLGA微球的性质有明显影响.结论:可通过调节PLGA分子量调控微球的性质.     

盐酸恩丹西酮与其它药物配伍的稳定性

盐酸恩丹西酮与其它药物配伍的稳定性党宏万，文友民（宁夏医学院附属医院药剂科银川７５０００４）盐酸恩丹西酮（Ｏｎｄａｎｓｅｔｒｏｎｈｙ－ｄｒｏｃｈｌｏｒｉｄｅ）为高度选择性的５－羟色胺３（５－ＨＴ３）受体拮抗剂，主要用于化疗药物和放射治疗引起的恶心呕吐...     

盐酸恩丹西酮药效学实验研究

本文报道盐酸恩丹西酮胶囊(深圳制药厂)对抗顺氯氨铂和环磷酰胺所致呕吐的动物药效学实验研究,并与枢复宁片(Glaxo公司)对照比较,结果两药均取得相近似的药效(P<0.05).     

盐酸恩丹西酮药效学实验研究

本文报道盐酸恩丹西酮胶囊对抗顺氯氨铂和环磷酰胺所致呕吐的动物药学实验研究，并与枢复宁片对照比较，结果两药取得相近似的药效。     

替莫唑胺乳酸-羟基乙酸共聚物微球的制备及表征

采用乳化-溶剂挥发法制备替莫唑胺微球,考察了制备工艺中影响微球粒径、载药量和包封率的主要因素,筛选处方工艺.按优化工艺制得的微球形态圆整,表面光滑,平均粒径62.2μm,载药量7.5%,包封率83.5%,体外试验表明该载药微球有明显的缓释效果.     

紫外分光光度法测定环丙沙星耳用药膜中盐酸环丙沙星的含量

盐酸环丙水利生含量可用一阶导数法测定，但本剂中有亚甲蓝干扰，不适用这种方法测定。本文采用紫外分光光度法测定耳用药膜剂中盐酸环丙沙星含量，波长选择在２７７ｎｍ，６６２ｎｍ处测定，结果表明各组份加和性良好。平均回收率ｎ为１０２．４％，Ｓｎ为１．３９％。     

复方制剂紫外光谱分析测定系统的开发

目的：开发复方制剂紫外光谱分析测定系统。方法：采用Microsoft Visual Studio 2008作为开发平台,以ADO方式连接数据源。结果：本系统可实现复方制剂含量测定所需的各项功能,运算结果准确。结论：该系统运行稳定可靠,界面友好,值得推广。     

紫外分光光度法测定利凡诺注射液中利凡诺的含量

目的 采用分光光度法测定利凡诺注射液中利凡诺的含量。方法：以水为溶剂,加入盐酸和亚硝酸钠,采用分光光度法,在518nm测定利凡诺注射液含量。结果 线性范围16～20ug／ml,(r=0．9996),平均回收率在99％以上,变异系数小于0．8％。结论 本法简便、准确、快速、稳定,可以作为利凡诺注射液中利凡诺的含量测定方法。     

Surface Modification of Poly(lactide-co-glycolide) Nanospheres by Biodegradable Poly(lactide)-Poly(ethylene glycol) Copolymers

The modification of surface properties of biodegradable poly(lactide-co-glycolide) (PLGA) and model polystyrene nanospheres by poly(lactide)-poly(ethlene glycol) (PLA:PEG) copolymers has been assessed using a range of in vitro characterization methods followed by in vivo studies of the nanospheres biodistribution after intravenous injection into rats. Coating polymers with PLA:PEG ratio of 2:5 and 3:4 (PEG chains of 5000 and 2000 Da, respectively) were studied. The results reveal the formation of a PLA: PEG coating layer on the particle surface resulting in an increase in the surface hydrophilicity and decrease in the surface charge of the nanospheres. The effects of addition of electrolyte and changes in pH on stability of the nanosphere dispersions confirm that uncoated particles are electrostatically stabilized, while in the presence of the copolymers, steric repulsions are responsible for the stability. The PLA:PEG coating also prevented albumin adsorption onto the colloid surface. The evidence that this effect was observed for the PLA:PEG 3:4 coated nanospheres may indicate that a poly(ethylene glycol) chain of 2000 Da can provide an effective repulsive barrier to albumin adsorption. The in vivo results reveal that coating of PLGA nanospheres with PLA:PEG copolymers can alter the biodistribution in comparison to uncoated PLGA nanospheres. Coating of the model polystyrene nanospheres with PLA:PEG copolymers resulted in an initial high circulation level, but after 3 hours the organ deposition data showed values similar to uncoated polystyrene spheres. The difference in the biological behaviour of coated PLGA and polystyrene nanospheres may suggest a different stability of the adsorbed layers on these two systems. A similar biodistribution pattern of PLA:PEG 3:4 to PEG 2:5 coated particles may indicate that poly(ethylene glycol) chains in the range of 2000 to 5000 can produce a comparable effect on in vivo behaviour.     

紫外分光光度法测定茶碱的血药浓度

目的建立适合基层医院普及的茶碱血药浓度测定方法。方法氯仿／异丙醇混合溶媒提取，碱液反提取，调节pH值避免巴比妥类药物干扰，应用紫外分光光度法测定茶碱浓度。结果茶碱浓度在5～40mg／L之间，标准曲线方程是C=55．8659A-0．0112（r=0．9992，n=6）。平均回收率是98．61％（RSD=2．09％，n=5）。变异系数是2．83％。结论本方法所需条件简便，测定快速、准确，适合基层普及。     

Release of Human Serum Albumin from Poly(lactide-co-glycolide) Microspheres

Human serum albumin (HSA) was encapsulated in a 50:50 copolymer of DL-lactide/glycolide in the form of microspheres. These microspheres were used as a model formulation to study the feasibility of controlling the release of large proteins over a 20- to 30-day period. We show that HSA can be successfully incorporated into microspheres and released intact from these microspheres into various buffer systems at 37°C. A continuous release of the protein could be achieved in physiological buffers at 37°C over a 20- to 30-day period from microspheres with high protein loadings (11.6%). These results demonstrate the potential of poly(DL-lactide-co-glycolide) microspheres for continuous delivery of large proteins.     

5-Fu/PLGA 微球的制备

以可生物降解高分子材料乳酸—羟乙酸共聚物(PLGA)为载体,以5—氟脲嘧啶(5-Fu)为活性药物,用相分离—凝聚法制备了可供肿瘤动脉栓塞化疗用微球,并进行了初步的微球体外药物释放试验。     

紫外分光光度法测定氧氟沙星滴眼液的含量

紫外分光光度法测定氧氟沙星滴眼液中氧氟沙星的含量,以0.1mol/L 醋酸为溶剂,测定波长293nm,吸收系数(E1cm1%)为876,测得平均回收率为99.9%,CV=0.36%(n=5)。滴眼液附加剂对测定无干扰。     

紫外分光光度法测定替米沙坦胶囊含量及溶出度

目的:建立以紫外分光光度法测定替米沙坦胶囊含量及溶出度的方法。方法:采用紫外分光光度法,以0.1mol·L-1盐酸溶液作为溶剂,测定波长为291nm。结果:替米沙坦检测浓度在2～16μg·mL-1范围内线性关系良好(r=0.9999),平均回收率为99.9%(RSD=0.24%,n=9)。结论:所建立的方法操作简便、结果准确。     

Dose and Load Studies for Subcutaneous and Oral Delivery of Poly(lactide-co-glycolide) Microspheres Containing Ovalbumin

Poly(lactide-co-glycolide) microspheres containing different loads of OVA (0.05, 0.1, 0.5 and 1.0% w/w) were manufactured by a w/o/w emulsion/solvent evaporation method. Low load efficiencies of less than 20% were observed. Normal size distributions with mean volume diameters ranging from 3.7 to 4.7 µm were obtained for different batches. The in vitro release of OVA from different loaded microspheres showed an expected burst release with all batches. The in vivo dose study (1, 10, 25, 50 µg of OVA) was performed by subcutaneous and oral inoculation in mice by single (0 week) or double (0 and 3 weeks) administration of PLGA 50/50 microspheres containing 0.1% OVA. Subcutaneous administration showed an immune response (serum Ig levels by ELISA) statistically (Fishers paired t-test; P < 0.05) above OVA saline negative controls at 3, 6 and 12 weeks after administration. Oral administration of microspheres produced statistically higher systemic immune responses at the higher doses. Single and double inoculation orally and subcutaneously produced similar serum antibody levels. The in vivo load study was performed by subcutaneous and oral administration to mice of 25 µg OVA contained in various loaded (0.05, 0.1, 0.5 and 1.0% w/w) microspheres. Serum immune responses at 3, 6, and 12 weeks after inoculation were statistically above OVA saline controls and were inversely proportional to the OVA load using either route. This observation suggested a relationship between the number of microspheres delivered and the in vivo serum response. Single subcutaneous administration of 0.05 or 0.1% OVA loaded PLGA 50/50 microspheres induced larger immune responses compared with complete Freunds adjuvant.